Drug Safety in Pregnancy

| Home | | Pharmacovigilance |

Chapter: Pharmacovigilance: Drug Safety in Pregnancy

Following the recognition in the 1960s that thalidomide, when used by pregnant women, induced a characteristic pattern of severe congenital anomalies in many of the offspring, pharmaceutical manufacturers, regulatory agencies.


Drug Safety in Pregnancy

INTRODUCTION

Following the recognition in the 1960s that thalidomide, when used by pregnant women, induced a characteristic pattern of severe congenital anomalies in many of the offspring, pharmaceutical manufacturers, regulatory agencies and a variety of public health entities have faced the challenge and respon-sibility of assessing the safety of medication with respect to the developing fetus (Lenz, 1961; McBride, 1961). This is a daunting task for a variety of reasons, not the least of which is the number and variety of medications to which a pregnant woman is likely to be exposed. Although pharmacovigilance for a spectrum of adverse reproductive outcomes, ranging from spontaneous abortion to long-term postnatal func-tional deficits or learning disabilities, is appropriate in assessing pharmaceutical safety during pregnancy, the focus of this chapter will be limited to major congenital anomalies. As congenital anomalies are the leading cause of infant mortality and number of years of potential life lost in the United States, the prevention of even the small proportion that are likely to be attributable to maternal medication use is a worthy goal of any pharmacovigilance effort (Rosenberg et al., 1996; Yang, Khoury and Mannino, 1997).

Contact Us, Privacy Policy, Terms and Compliant, DMCA Policy and Compliant

TH 2019 - 2022 pharmacy180.com; Developed by Therithal info.